FindTrial
Sign In

Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori

Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1080222003
Enrollment
100
Registered
2013-01-21
Start date
2013-01-21
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric mucosa-associated lymphoid tissue lymphoma

Interventions

investigational material(s) Generic name etc : Pariet INN of investigational material : Therapeutic category code : 232 Agents for peptic ulcer Dosage and Administration for Investigational material

Sponsors

Eisai Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Gastric low-grade mucosa-associated lymphoid tissue (MALT) lymphoma with Helicobacter pylori positive The stages of MALT lymphoma are Lugano International Conference classification Stage I or II 1 and Wotherspoon grade 4 or 5

Exclusion criteria

Exclusion criteria: With diffuse large B-cell lymphoma Corresponding to contraindication of each drug Have been treated to gastric mucosa-associated lymphoid tissue (MALT) lymphoma

Design outcomes

Primary

MeasureTime frame
Response rate of gastric low-grade MALT lymphoma by eradication of Helicobacter pylori Transition rate to secondary therapy for eradication of Helicobacter pylori—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026